Last reviewed · How we verify
Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well bevacizumab given together with combination chemotherapy works in treating patients with metastatic colorectal cancer.
Details
| Lead sponsor | Hopital Jean Minjoz |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 47 |
| Start date | 2007-04 |
Conditions
- Colorectal Cancer
Interventions
- bevacizumab
- capecitabine
- fluorouracil
- irinotecan hydrochloride
- diagnostic laboratory biomarker analysis
Primary outcomes
- Objective response (complete and partial) rate
Countries
France